Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives $107.00 Average PT from Analysts

Monopar Therapeutics Inc. (NASDAQ:MNPR) has been assigned a consensus rating of “Buy” from the thirteen ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $107.00.

A number of equities analysts recently issued reports on MNPR shares. Chardan Capital reissued a “buy” rating and issued a $100.00 price objective on shares of Monopar Therapeutics in a report on Thursday, January 29th. Barclays set a $125.00 price target on shares of Monopar Therapeutics and gave the stock an “overweight” rating in a research note on Monday, October 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, January 22nd. Leerink Partners initiated coverage on Monopar Therapeutics in a research report on Monday, November 10th. They set an “outperform” rating and a $115.00 target price on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, January 21st.

Insider Activity

In related news, CFO Quan Anh Vu acquired 1,500 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The stock was bought at an average cost of $69.95 per share, for a total transaction of $104,925.00. Following the purchase, the chief financial officer owned 1,500 shares in the company, valued at $104,925. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Mountain Pacific Investment Advisers LLC purchased a new stake in shares of Monopar Therapeutics in the fourth quarter worth $398,000. TCG Crossover Management LLC purchased a new position in shares of Monopar Therapeutics during the 3rd quarter valued at $12,496,000. Alyeska Investment Group L.P. bought a new position in Monopar Therapeutics in the 3rd quarter worth $998,000. Vivo Capital LLC bought a new position in Monopar Therapeutics in the 3rd quarter worth $7,391,000. Finally, Ally Bridge Group NY LLC increased its stake in Monopar Therapeutics by 86.6% in the 3rd quarter. Ally Bridge Group NY LLC now owns 64,455 shares of the company’s stock worth $5,264,000 after buying an additional 29,918 shares in the last quarter. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Price Performance

MNPR stock opened at $56.88 on Tuesday. Monopar Therapeutics has a 1 year low of $26.06 and a 1 year high of $105.00. The company has a market cap of $380.13 million, a P/E ratio of -16.53 and a beta of 1.52. The stock’s fifty day moving average price is $69.79 and its 200-day moving average price is $65.95.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). As a group, analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current year.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.